BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1844@azbio.org DTSTART;TZID=America/Phoenix:20231025T080000 DTEND;TZID=America/Phoenix:20231025T090000 DTSTAMP:20231006T144218Z URL:https://www.azbio.org/events/nci-technology-opportunity-webinar SUMMARY:NCI Technology Opportunity Webinar - - 25 Oct 23 08:00 DESCRIPTION:\nAnti-EGFR Antibodies for the Treatment of Human Cancers\nRegi ster to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald\, Ph.D. These antibodies bind a particular structure on the external domain of epidermal growth fac tor receptor (EGFR) which is displayed on cancer cells that express high E GFR levels or the variant termed ‘EGFRvIII.’ Importantly\, these antib odies do not bind normal cells and therefore are used to deliver toxic pay loads (as antibody-drug conjugates - ADCs) to cancer cells without killing normal cells. In addition\, these antibodies are superior to currently ap proved drugs that target this receptor\, including ligand-blocking monoclo nal antibodies and small molecular weight kinase inhibitors. The webinar w ill highlight how tumors expressing high levels of human EGFR experience a significant reduction in size after treatment with several distinct ADCs made in Dr. Fitzgerald’s Lab. This invention was featured at the 2023 T echnology Showcase.\nWhen: Wednesday\, October 25th. 11am-12pm ET\n\nRegis ter Here\nPresenter\nDavid Fitzgerald\, Ph.D.\nSenior Investigator\nLabora tory of Molecular Biology\nCenter for Cancer Research (CCR)\nNational Canc er Institute\n\nWebinar Overview\nThe presentation will follow a logical s equence of how anti-EGFR antibodies are generated and modified to make the m cytotoxic for tumor cells with high levels of EGFR or the variant EGFRvI II. It will specifically focus on beginning with a key mouse monoclonal an tibody termed ‘40H3’ and then the transition to the humanization of th is antibody to produce the antibody termed ‘A10.’ These anti-EGFR anti bodies can be used as either independent agents or targeting domains in re combinant immunotoxins (RITs)\, antibody-drug conjugates (ADCs)\, bispecif ic antibodies\, and chimeric antigen receptors (CARs). Attendees will have an opportunity to ask questions.\n\nAbout the Featured Technology\nDr. Fi tzgerald and his team established that using one of the antibodies (40H3) as an antibody-drug conjugate has potential use as a potent therapeutic be cause of its ability to kill both breast cancer cells and epidermoid cance r cells and reduce tumor growth in mice. The 40H3 antibody is also able to bind to EGFR when overexpressed in cancers of various tissue origins and thus has broad therapeutic potential for a wide cancer patient population. Further\, the 40H3 antibody has been humanized producing an antibody term ed ‘A10’ which retains the full binding activity of 40H3.\n\n\n\n\n\nW hy Attend?\n\n Assess co-developing the technology.\n Interact with the inventor\, ask questions and provide feedback.\n Learn how to partner wit h NCI and other NIH Institutes.\n\n \;\n\nWho Should Attend?\n\n Busi ness development professionals\n Drug development professionals\n Biotec h/pharma/academia researchers\n Investors and entrepreneurs\n Foundation s\, philanthropies and patient advocacy groups\n\n\n\n\n END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20221025T080000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR